Profile data is unavailable for this security.
About the company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
- Revenue in USD (TTM)215.23m
- Net income in USD54.95m
- Incorporated2016
- Employees177.00
- LocationEntrada Therapeutics IncOne Design Center Place, Suite 17-500BOSTON 02210United StatesUSA
- Phone+1 (857) 305-1825
- Fax+1 (302) 655-5049
- Websitehttps://www.entradatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 698.16m | 28.00 | -- | 2.41 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.16m | -167.45m | 703.15m | 483.00 | -- | 1.81 | -- | 25.89 | -1.31 | -1.31 | 0.2137 | 3.01 | 0.042 | -- | 26.88 | 56,234.72 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 710.10m | 80.00 | -- | 3.13 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 710.59m | 73.00 | -- | 6.65 | -- | 105.40 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Humacyte Inc | 0.00 | -139.66m | 722.67m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 723.77m | 107.00 | -- | 2.30 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 729.77m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Stoke Therapeutics Inc | 16.74m | -105.46m | 735.18m | 110.00 | -- | 3.17 | -- | 43.91 | -2.10 | -2.10 | 0.3294 | 4.38 | 0.0628 | -- | 42.55 | 152,209.10 | -39.56 | -31.62 | -46.04 | -33.92 | -- | -- | -629.86 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 737.45m | 44.00 | -- | 2.18 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Entrada Therapeutics Inc | 215.23m | 54.95m | 741.66m | 177.00 | 12.44 | 1.75 | 12.68 | 3.45 | 1.59 | 1.59 | 5.97 | 11.30 | 0.4141 | -- | 56.43 | 1,353,660.00 | 10.57 | -- | 13.68 | -- | -- | -- | 25.53 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| BIOAGE Labs Inc | 0.00 | -62.16m | 758.17m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Perspective Therapeutics Inc | -1.87m | -49.02m | 758.56m | 116.00 | -- | 2.22 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
| Annexon Inc | 0.00 | -115.16m | 763.88m | 71.00 | -- | 2.11 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| IGM Biosciences Inc | 2.91m | -220.40m | 772.92m | 204.00 | -- | 6.31 | -- | 265.52 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 783.51m | 40.00 | -- | 6.04 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 792.31m | 267.00 | -- | -- | -- | 2.09 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Data as of Nov 08 2024. Currency figures normalised to Entrada Therapeutics Inc's reporting currency: US Dollar USD
44.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Jun 2024 | 4.87m | 13.08% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 3.11m | 8.35% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.83m | 4.92% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 1.55m | 4.16% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.49m | 4.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.10m | 2.96% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 1.03m | 2.78% |
| Redmile Group LLCas of 30 Jun 2024 | 560.97k | 1.51% |
| Geode Capital Management LLCas of 30 Jun 2024 | 529.94k | 1.43% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 445.22k | 1.20% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
